UA91676C2 - Композиция, которая содержит ингибитор jnk и циклоспорин - Google Patents

Композиция, которая содержит ингибитор jnk и циклоспорин

Info

Publication number
UA91676C2
UA91676C2 UAA200610429A UAA200610429A UA91676C2 UA 91676 C2 UA91676 C2 UA 91676C2 UA A200610429 A UAA200610429 A UA A200610429A UA A200610429 A UAA200610429 A UA A200610429A UA 91676 C2 UA91676 C2 UA 91676C2
Authority
UA
Ukraine
Prior art keywords
cyclosporin
composition
jnk inhibitor
jnk
cancer
Prior art date
Application number
UAA200610429A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристиан Роммель
Пьер-Ален Вит
Original Assignee
Эплайд Рисерч Системз Эрс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эплайд Рисерч Системз Эрс Холдинг Н.В. filed Critical Эплайд Рисерч Системз Эрс Холдинг Н.В.
Publication of UA91676C2 publication Critical patent/UA91676C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение касается композиции, которая содержит ингибитор JNK и циклоспорин, в частности, для лечения нейронных расстройств, автоиммунных заболеваний, онкологических заболеваний и сердечно-сосудистых заболеваний.
UAA200610429A 2004-04-08 2005-04-08 Композиция, которая содержит ингибитор jnk и циклоспорин UA91676C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101468 2004-04-08
PCT/EP2005/051572 WO2005097116A1 (en) 2004-04-08 2005-04-08 Composition comprising a jnk inhibitor and cyclosporin

Publications (1)

Publication Number Publication Date
UA91676C2 true UA91676C2 (ru) 2010-08-25

Family

ID=34928946

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610429A UA91676C2 (ru) 2004-04-08 2005-04-08 Композиция, которая содержит ингибитор jnk и циклоспорин

Country Status (13)

Country Link
US (1) US20080039377A1 (ru)
EP (1) EP1850846A1 (ru)
JP (2) JP5080241B2 (ru)
KR (2) KR20060134198A (ru)
CN (1) CN1960726A (ru)
AU (2) AU2005230416B2 (ru)
BR (1) BRPI0509755A (ru)
CA (1) CA2561907A1 (ru)
EA (1) EA017893B1 (ru)
IL (1) IL178417A0 (ru)
NO (1) NO20065117L (ru)
UA (1) UA91676C2 (ru)
WO (1) WO2005097116A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US20090176762A1 (en) * 2006-06-02 2009-07-09 Laboratoires Serono Sa JNK Inhibitors for Treatment of Skin Diseases
US20100121057A1 (en) * 2007-04-17 2010-05-13 Merck Serono Sa Process for the Preparation of Piperazine Benzothiazoles
EP2195009B1 (en) 2007-09-26 2014-07-30 Oregon Health and Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8828924B2 (en) * 2009-05-14 2014-09-09 University Of Maryland, Baltimore Methods of treating a diabetic embryopathy
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
CA2834619A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Controlled release of immunosuppressants from synthetic nanocarriers
WO2012164398A2 (en) * 2011-06-01 2012-12-06 Netherlands Cancer Institute Modulation of the ubiquitin-proteasome system (ups)
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
JP6580558B2 (ja) 2013-05-03 2019-09-25 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
EP3592389A1 (en) 2017-03-11 2020-01-15 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR20230164862A (ko) * 2022-05-26 2023-12-05 연세대학교 산학협력단 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193267A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases

Also Published As

Publication number Publication date
BRPI0509755A (pt) 2007-10-16
CA2561907A1 (en) 2005-10-20
JP5080241B2 (ja) 2012-11-21
KR20060134198A (ko) 2006-12-27
EP1850846A1 (en) 2007-11-07
IL178417A0 (en) 2007-02-11
JP2007532517A (ja) 2007-11-15
AU2010212339B2 (en) 2012-07-19
AU2005230416B2 (en) 2010-05-13
EA200601841A1 (ru) 2007-04-27
JP2012136550A (ja) 2012-07-19
AU2005230416A1 (en) 2005-10-20
EA017893B1 (ru) 2013-04-30
US20080039377A1 (en) 2008-02-14
WO2005097116A1 (en) 2005-10-20
CN1960726A (zh) 2007-05-09
KR20120135441A (ko) 2012-12-13
NO20065117L (no) 2006-11-07
AU2010212339A1 (en) 2010-09-09

Similar Documents

Publication Publication Date Title
UA91676C2 (ru) Композиция, которая содержит ингибитор jnk и циклоспорин
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
HK1106131A1 (en) Mitotic kinesin inhibitors and methods of use thereof
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
PL1635824T3 (pl) 5-Członowe heterocykliczne inhibitory P-38
PL1742644T3 (pl) Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny
TW200510416A (en) P38 inhibitors and methods of use thereof
IL177849A0 (en) Methods and compositions for treatment of autoimmune diseases
MXPA05013824A (es) Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
EP1879886A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
WO2006005602A3 (en) Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
TW200735886A (en) Prevention and treatment of ocular side effects with a cyclosporin
UA94049C2 (ru) Применение ингибиторов glepp-1 для лечения аутоиммунных и/или воспалительных расстройств
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
IL181183A (en) Use of an elastase inhibitor in the manufacture of a medicament for the treatment of leukemia
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
IL175923A0 (en) Compositions and methods for treatment of cardiovascular disorders and diseases